| Total (N=123) | TARD (n = 50) | TaTME (n = 73) | P value |
---|---|---|---|---|
Sex, n (%) | Â | Â | Â | 0.024 |
 Male | 83 (67.5) | 28 (56.0) | 55 (75.3) |  |
 Female | 40 (32.5) | 22 (44.0) | 18 (24.7) |  |
Agea | 66 (33–86) | 63.5 (33–77) | 66 (41–86) | 0.298 |
Body mass indexa | 21.9 (16.7–41.8) | 21.5 (16.7–37.2) | 22.5 (16.8–41.8) | 0.376 |
Preoperative treatment, n (%) | Â | Â | Â | 1.000 |
 Positive | 40 (32.5) | 16 (32.0) | 24 (32.9) |  |
  CRT | 29 (23.6) | 16 (32.0) | 13 (17.8) |  |
  NAC | 11 (8.9) | 0 (0.0) | 11 (15.1) |  |
 Negative | 83 (67.5) | 34 (68.0) | 49 (67.1) |  |
Resection of the AIS | Â | Â | Â | Â |
 ISR | 48 (39.0) | 29 (58.0) | 19 (26.0) | <0.001 |
 Ultra-LAR with CAA | 75 (61.0) | 21 (42.0) | 54 (74.0) |  |
Tumor related factor | Â | Â | Â | Â |
 T, n (%) |  |  |  | 0.299 |
  1b | 21 (17.0) | 10 (20.0) | 11 (15.1) |  |
  2 | 38 (30.9) | 14 (28.0) | 24 (32.9) |  |
  3 | 54 (43.9) | 23 (46.0) | 31 (42.5) |  |
  4a | 5 (4.1) | 0 (0.0) | 5 (6.8) |  |
  pCR | 5 (4.1) | 3 (6.0) | 2 (2.7) |  |
 N, n (%) |  |  |  | 1.000 |
  Positive | 33 (26.8) | 13 (26.0) | 20 (27.4) |  |
  Negative | 90 (73.2) | 37 (74.0) | 53 (72.6) |  |
 M, n (%) |  |  |  | 1.000 |
  Positive | 2 (1.6) | 1 (2.0) | 1 (1.4) |  |
  Negative | 121 (98.4) | 49 (98.0) | 72 (98.6) |  |
 pStage, n (%) |  |  |  | 0.874 |
  I | 52 (42.3) | 22 (44.0) | 30 (41.1) |  |
  II | 33 (26.8) | 12 (24.0) | 21 (28.8) |  |
  III | 31 (25.2) | 12 (24.0) | 19 (26.0) |  |
  IV | 2 (1.6.) | 1 (2.0) | 1 (1.4) |  |
  pCR | 5 (4.1) | 3 (6.0) | 2 (2.7) |  |